ArticleEndocrinology2010
Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades.
Article in Endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.Journal of endocrinological investigation · 2018Pooled it
- Measuring thyroid-stimulating hormone receptor antibodies using the IMMULITEThyroid research · 2026Article
- Evaluation of the analytical and clinical characteristics of the siemens immulite®2000 tsi method for determining thyrotropin receptor antibodies.Journal of medical biochemistry · 2025Article
- Atrophic hypothyroidism associated with thyrotropin receptor antibodies.Einstein (Sao Paulo, Brazil) · 2025Article
- The TSH Receptor Antibody Reactome Contributes to Retro-Orbital Inflammation.Journal of the Endocrine Society · 2024Article
- The interlink between thyroid autoimmunity and type 1 diabetes and the impact on male and female fertility.Hormones (Athens, Greece) · 2024Review
- The role of autophagy in Graves disease: knowns and unknowns.Frontiers in cell and developmental biology · 2024Review
- A novel bioassay for thyroid-blocking immunoglobulins.Frontiers in endocrinology · 2024Article
- TSH enhances neurite outgrowth.Frontiers in endocrinology · 2024Article
- Evaluation of the Abbott Alinity i Thyroid-Stimulating Hormone Receptor Antibody (TRAb) Chemiluminescent Microparticle Immunoassay (CMIA).Diagnostics (Basel, Switzerland) · 2023Article
- Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.International journal of molecular sciences · 2023Review
- Possible molecular exploration of herbal pair Haizao-Kunbu in the treatment of Graves' disease by network pharmacology, molecular docking, and molecular dynamic analysis.Frontiers in endocrinology · 2023Article
- Characterization of Apparently Paradoxical Thyrotropin Binding Inhibitory Immunoglobulins With Neutral Bioactivity.Journal of the Endocrine Society · 2022Article
- Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy.Journal of medical biochemistry · 2022Article
- Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.Thyroid : official journal of the American Thyroid Association · 2022Article
- Rescue of thyroid cells from antibody induced cell death via induction of autophagy.Journal of autoimmunity · 2022Article
- Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.Journal of endocrinological investigation · 2022Article
- Article
- Cellular and molecular basis of thyroid autoimmunity.European thyroid journal · 2022Review
- Clinical Course of Euthyroid Subjects With Positive TSH Receptor Antibody: How Often Does Graves' Disease Develop?Journal of the Endocrine Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
TSH receptor (TSHR) antibodies (Abs) may be stimulating, blocking, or neutral in their functional influences and are found in patients with autoimmune thyroid disease, especially Graves' disease (GD). Stimulators are known to activate the thyroid epithelial cells via both Gs- and Gq-coupled signaling pathways, whereas blockers inhibit the action of TSH and may act as weak agonists. However, TSHR neutral Abs do not block TSH binding and are unable to induce cAMP via Gsα. The importance of such neutral Abs in GD remains unclear because their functional consequence has been assumed to be zero. We hypothesized that: 1) neutral TSHR Abs are more common to GD than generally recognized; 2) they may induce distinct signaling imprints at the TSHR not seen with TSH itself; and 3) these signaling events may alter cellular function. To evaluate these hypotheses, we first confirmed the presence of neutral TSHR Abs in sera from patients with GD and then, using mouse and hamster neutral TSHR monoclonal Abs (N-mAbs) performed detailed signaling studies, including a proteomic Ab array, with rat thyrocytes (FRTL-5) as targets. This allowed us to examine a battery of signaling cascades and their downstream effectors. Neutral TSHR Abs were indeed frequently present in sera from patients with GD. Sixteen of 27 patients (59%) had detectable neutral TSHR Abs by competition assay with N-mAbs. On examining signaling cascades, we found that N-mAbs induced signal transduction, primarily via the protein kinase A II cascade. In addition to the activation of phosphatidylinositol 3K/Akt, N-mAbs, unlike TSH, had the ability to exclusively activate the mammalian target of rapamycin/p70 S6K, nuclear factor-κB, and MAPK-ERK1/2/p38α signaling cascades and their downstream effectors p90 ribosomal kinase/MAPK-interacting kinase-1/mitogen and stress-activated kinase-1 and N-mAbs activated all forms of protein kinase C isozymes. To define the downstream effector mechanisms produced by these signaling cascades, cytokine production, proliferation, and apoptosis in thyrocytes were investigated. Although N-mAbs produced less cytokines and proliferation compared with TSH, they had the distinction of inducing thyroid cell apoptosis under the experimental conditions used. When dissecting out possible mechanisms of apoptosis, we found that activation of multiple oxidative stress markers was the primary mechanism orchestrating the death signals. Therefore, using oxidative stress-induced apoptosis, N-mAbs may be capable of exacerbating the autoimmune response in GD via apoptotic cells inducing antigen-driven mechanisms. This may help explain the inflammatory nature of this common disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.